Pulse Biosciences Files 510(k) Submission for CellFX® nsPFA™ Cardiac Clamp

 -Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA Cardiac Clamp.

https://www.businesswire.com/news/home/20240102888326/en/